Antimicrobial Resistance Strategy launched in UK

11 September 2013

The UK’s Department of Health has launched a five year Antimicrobial Resistance Strategy. The scale of the threat of antimicrobial resistance (AMR) and the case for action was set out in the Annual Report of the Chief Medical Officer, 2011, in March and the UK Five Year Antimicrobial Resistance Strategy 2013 to 2018 sets out actions to address the key challenges to AMR.

The DoH said that resistance to all antimicrobials, including antivirals and antifungals, is increasing, but of greatest concern is the rapid development of bacterial resistance to antibiotics. If the number of hard-to-treat infections continues to grow, then it will become increasingly difficult to control infection in a range of routine medical care settings. It maintains that antibiotic resistance can be managed to limit the threat to, and minimize the impact on, human and animal health.

Responsible use of antibiotics

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical